- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04191525
Phase II Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus
A 12 Week, Randomized, Double-blind, Placebo-controlled, Phase II Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus With Different Course of Disease and Treatment
Diabetes Mellitus type 2 (T2DM) is a chronic and progressive disease, characterized mainly by hyperglycemia. Metabolic imbalance causes an increased risk of microvascular and macrovascular complications associated with the increased prevalence of cardiovascular disease (CVD) in diabetics.
Although genetic predisposition determines individual susceptibility to T2DM, external factors such as an unhealthy diet and a sedentary lifestyle condition the onset of the disease.
Since T2DM is a multifactorial disease, many authors have studied the possible role of the microbiota and its alterations in the pathophysiology of the disease. There is evidence that in T2DM there are alterations in the proportion of Firmicutes, Bacteroidetes and Proteobacteria, and a smaller amount of bifidobacteria with anti-inflammatory properties.
Probiotics are living microorganisms present in food that, if consumed in sufficient quantities, can improve health. In general, probiotics protect the patient through immunomodulation, protecting him from infections, increasing the activation of mononuclear cells and lymphocytes.
The investigational product is a supplement to the probiotic Bifidobacterium animalis subsp. lactis (BPL-1) CECT 8145. There are numerous studies carried out on different strains of GLP-1 that demonstrate its safety. Many of them are commonly used in the food industry, not only because of their proven safety, but also because of their viability until consumption.
This clinical trial is proposed as an interdisciplinary study that can contribute to the characterization of the efficacy of treatment with probiotics in patients with T2DM of different stages of evolution, without and with hepatic involvement.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28006
- Hospital Universitario de La Princesa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients between the ages of 18-75 (inclusive)
- BMI ≥ 27
- Glycated hemoglobin > 5,6 and/or fasting glucose > 100 mg/dl and/or being on active treatment with at least one antidiabetic medication
- Subjects must be able to provide written informed consent
- Females of childbearing potential must have a previous negative pregnancy test and must agree to use adequate contraception during their participation in the study
Exclusion Criteria:
- Crohn's disease, liver cirrhosis, human immunodeficiency virus (HIV) or any other active systemic bacterial, viral or fungal infections
- BMI > 42
- Severe hypoglycemias within 3 months prior to the start date of the study
- Abnormal glycated hemoglobin measurements (over 8%) prior to the start date of the study
- Prescription of a new antidiabetic medication in the last 6 months
- Celiac disease or any other food intolerances
- Use of antibiotics, probiotics and/or prebiotics within 2 weeks prior to the start date of the study
- Chronic liver disease with a C Child-Plug score, chronic kidney disease with creatinine clearance < 50 ml/min as well as any other clinically significant conditions including pulmonary, neurological and cardiovascular diseases according to the investigators medical opinion
- Patients with history or presence of malignancy who have been treated with systemic antineoplastic therapy within 6 months prior to the start date of the study
- Pregnancy and breastfeeding
- Not being able to provide written informed consent to participate in the study or to cooperate and comply with the study procedures for any other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BPL-1 Probiotic capsules
BPL-1 Probiotic 1 capsule/day
|
BPL-1 Probiotic 1 capsule/day
|
Placebo Comparator: Placebo
1 capsule/day
|
Placebo masked with the same presentation as the experimental product 1 capsule/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting glucose
Time Frame: 12 weeks
|
Fasting glucose
|
12 weeks
|
Glycated haemoglobin
Time Frame: 12 weeks
|
Glycated haemoglobin
|
12 weeks
|
Insulin
Time Frame: 12 weeks
|
Insulin
|
12 weeks
|
HOMA-IR
Time Frame: 12 weeks
|
HOMA-IR
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total cholesterol
Time Frame: 12 weeks
|
Total cholesterol
|
12 weeks
|
HDL-cholesterol
Time Frame: 12 weeks
|
HDL-cholesterol
|
12 weeks
|
LDL-cholesterol
Time Frame: 12 weeks
|
LDL-cholesterol
|
12 weeks
|
Triglycerides
Time Frame: 12 weeks
|
Triglycerides
|
12 weeks
|
Body Mass Index (BMI)
Time Frame: 12 weeks
|
Body Mass Index (BMI)
|
12 weeks
|
Body Fat Percentage (%BF)
Time Frame: 12 weeks
|
Body Fat Percentage (%BF)
|
12 weeks
|
Blood pressure
Time Frame: 12 weeks
|
Blood pressure
|
12 weeks
|
Waist perimeter
Time Frame: 12 weeks
|
Waist perimeter
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mediterranean diet adherence score
Time Frame: 12 weeks
|
Mediterranean diet adherence score
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mónica Marazuela Azpíroz, MD PhD, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PROBIDEM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on BPL-1 Probiotic capsules
-
Danisco Sweeteners OyEurofins OptimedCompletedConstipation | Gastrointestinal DisorderFrance
-
Probi ABCompleted
-
Probi ABTerminatedGynecologic Cancer | Gastrointestinal ToxicitySweden
-
Probi ABCompletedAntibiotic-associated Loose/Watery StoolsPoland
-
Sahlgrenska University Hospital, SwedenBioGaia ABCompleted
-
Taipei Medical University Shuang Ho HospitalTaipei Medical University; Delta ElectronicsUnknownProbiotics | Vancomycin-Resistant EnterococciTaiwan
-
Maastricht University Medical CenterCompleted
-
Ole Kudsk JensenThe Danish Rheumatism AssociationCompleted
-
The Canadian College of Naturopathic MedicineWakunaga Pharmaceutical Co., Ltd.; Dicentra Inc.CompletedDigestive System Diseases | Irritable Bowel Syndrome | Colonic Diseases, Functional | Colitis, Mucous | Colon, IrritableCanada